Eli Lilly is entering the emerging psychedelic medicine sector through an agreement to acquire AtaiBeckley, a clinical-stage biotechnology company developing treatments for serious mental health conditions. The transaction is valued at approximately $2.8 billion upfront and could reach $3.8 billion if specified clinical development and regulatory milestones are achieved.

Under the agreement, Lilly will pay $6.75 in cash for each outstanding AtaiBeckley share. Shareholders could receive an additional $2.50 per share through contingent value rights linked to the progress of the company’s two leading drug candidates. The upfront purchase price represents an approximately 40% premium to AtaiBeckley’s 30-day volume-weighted average share price through July 15, 2026.

The acquisition reflects growing investment in next-generation mental health treatments as pharmaceutical and biotechnology companies look beyond conventional antidepressants. AtaiBeckley is developing rapid-acting neuroplastogens intended to support neural connectivity in areas of the brain associated with mood regulation.

Explore the Emerging Mental Health Devices and Platforms Market

AtaiBeckley’s most advanced candidate, BPL-003, is an intranasal formulation of mebufotenin benzoate, a synthetic form of the psychedelic compound 5-MeO-DMT. It is being developed for treatment-resistant depression, a condition affecting patients who continue to experience significant symptoms despite receiving multiple existing therapies.

BPL-003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has entered Phase 3 development activities. In a Phase 2b study, the candidate produced rapid reductions in depressive symptoms following an in-clinic treatment session lasting approximately two hours. The reported benefits continued for several months, although the findings remain investigational and must be confirmed through larger late-stage trials.

Download the Complete TOC of the Emerging Mental Health Devices and Platforms Market

The acquisition also gives Lilly access to VLS-01, a DMT-based buccal film currently advancing through Phase 2b development for treatment-resistant depression. AtaiBeckley’s pipeline further includes EMP-01, an R-MDMA candidate being evaluated for social anxiety disorder.

For Lilly, the transaction expands its neuroscience portfolio and provides access to a developing category of interventional psychiatric treatments. AtaiBeckley could benefit from Lilly’s global clinical development resources, regulatory capabilities, financial strength, and commercial infrastructure.

The transaction is expected to close in the third quarter of 2026, subject to AtaiBeckley shareholder approval, regulatory clearance, and customary closing conditions. Its long-term value will depend on whether the acquired candidates successfully complete clinical trials, receive regulatory approval, satisfy drug-scheduling requirements, and gain acceptance within healthcare delivery systems.

Request a Sample of the Emerging Mental Health Devices and Platforms Market Before Competitors Move

General Fusion has entered the public markets after completing its business combination with Spring Valley Acquisition Corp. III, marking a significant moment for the global fusion energy industry. The Vancouver-based company is positioned as the first publicly listed pure-play fusion energy business, giving investors direct exposure to a technology that could reshape the future of electricity generation. Its ordinary shares and warrants are scheduled to begin trading on Nasdaq under the ticker symbols GFUZ and GFUZW.

The transaction was completed on July 10, 2026, following shareholder approval earlier in the month. It is expected to provide General Fusion with approximately $150 million in cash, including proceeds from Spring Valley’s trust account and private investment funding. The company plans to use this capital to advance its fusion development program, strengthen operations, and achieve important technical milestones through 2028.

Explore the Fusion Energy Market to understand the technologies, investment trends, and companies shaping the next generation of clean power.

Founded in 2002, General Fusion has spent more than two decades developing its Magnetized Target Fusion technology. Unlike competing approaches that rely heavily on large superconducting magnets or high-powered laser systems, General Fusion uses mechanical compression to compress magnetized plasma inside a chamber surrounded by a liquid-metal liner. The company believes this approach could offer a simpler, more cost-effective, and commercially scalable pathway to fusion power generation.

At the center of its development strategy is Lawson Machine 26, also known as LM26. The demonstration platform is designed to compress plasma using a lithium liner and test whether General Fusion’s technology can achieve the extreme temperatures and confinement conditions required for fusion reactions. The company aims to heat the plasma first to 10 million degrees Celsius and then to 100 million degrees, before progressing toward the Lawson criterion, a key scientific threshold associated with producing net fusion energy within plasma.

Download the Complete Table of Contents to review the market segmentation, technology landscape, competitive environment, and regional opportunities covered in the Fusion Energy Market study.

General Fusion’s Nasdaq listing comes as global electricity demand is increasing due to artificial intelligence, data centers, industrial electrification, and the expansion of energy-intensive infrastructure. Fusion energy is attracting attention because it could potentially deliver reliable, low-carbon power by combining atomic nuclei rather than splitting them. However, commercial fusion power plants are not yet operational, and the industry continues to face considerable scientific, engineering, regulatory, and financial challenges.

Becoming a publicly traded company gives General Fusion access to a broader pool of capital, but it also places the company’s technical progress and commercialization timeline under closer scrutiny. Its next major test will be whether LM26 can achieve the planned milestones and demonstrate that Magnetized Target Fusion can progress from experimental development toward a commercially viable power plant.

Request a Sample of the Fusion Energy Market report for detailed insights into market growth, emerging technologies, funding activity, and the competitive outlook.